Orbimed Advisors LLC Invests $6.36 Million in Compass Pathways PLC Sponsored ADR $CMPS

Orbimed Advisors LLC bought a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,150,646 shares of the company’s stock, valued at approximately $6,363,000.

A number of other large investors also recently made changes to their positions in CMPS. Affinity Asset Advisors LLC boosted its holdings in Compass Pathways by 454.2% during the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after purchasing an additional 908,483 shares during the last quarter. Entropy Technologies LP purchased a new stake in Compass Pathways in the 1st quarter valued at about $110,000. Amova Asset Management Americas Inc. increased its stake in Compass Pathways by 49.1% in the 1st quarter. Amova Asset Management Americas Inc. now owns 368,828 shares of the company’s stock valued at $2,029,000 after buying an additional 121,491 shares during the last quarter. Parallel Advisors LLC increased its stake in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Compass Pathways by 49.1% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 368,828 shares of the company’s stock worth $2,040,000 after buying an additional 121,491 shares in the last quarter. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Performance

NASDAQ CMPS opened at $11.26 on Monday. Compass Pathways PLC Sponsored ADR has a 52-week low of $3.92 and a 52-week high of $15.40. The company has a 50-day simple moving average of $12.51 and a 200 day simple moving average of $9.03. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The company has a market capitalization of $1.52 billion, a PE ratio of -3.57 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, research analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CMPS. UBS Group set a $18.00 target price on Compass Pathways in a research note on Thursday, May 7th. Evercore raised Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target for the company in a research report on Wednesday, July 8th. Wolfe Research reiterated an “outperform” rating on shares of Compass Pathways in a report on Tuesday, July 7th. BTIG Research lifted their price target on Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Compass Pathways in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.15.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.